Nintedanib
- TRADE NAME: Ofev (Boehringer Ingelheim)
- INDICATIONS: Idiopathic pulmonary fibrosis
- CLASS: Angiogenesis inhibitor / antiangiogenic agent, Tyrosine kinase inhibitor
- HALF-LIFE: 9.5 hours
FDA APPROVAL DATE: 10/15/2014
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Anticoagulants, Carbamazepine, Erythromycin, Phenytoin, St John's Wort
PREGNANCY CATEGORY: D
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Click on the two DRUG REVIEW ARTICLE tabs (above) to see reviews of nintedanib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/25/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric